- Home
- CNOB vs OCUL Comparison
CNOB vs OCUL Comparison
Compare CNOB & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOB | OCUL |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | United States |
| Employees | 756 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNOB | OCUL |
|---|---|---|
| Price | $32.38 | $10.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $31.25 | $23.56 |
| AVG Volume (30 Days) | 541.3K | ★ 3.3M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,990,000.00 |
| Revenue This Year | $42.85 | $7.93 |
| Revenue Next Year | $7.27 | $96.07 |
| P/E Ratio | $17.02 | ★ N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $22.07 | $6.23 |
| 52 Week High | $33.97 | $16.44 |
Technical Indicators
Market Signals| Indicator | CNOB | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 57.45 |
| Support Level | $31.36 | $9.24 |
| Resistance Level | $33.97 | $10.62 |
| Average True Range (ATR) | 0.78 | 0.57 |
| MACD | -0.24 | 0.05 |
| Stochastic Oscillator | 41.59 | 45.47 |
Price Performance
Historical ComparisonAbout CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.